567 related articles for article (PubMed ID: 17089011)
41. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Menendez JA; Vellon L; Colomer R; Lupu R
Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
[TBL] [Abstract][Full Text] [Related]
42. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
Shiu LY; Liang CH; Chang LC; Sheu HM; Tsai EM; Kuo KW
Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
[TBL] [Abstract][Full Text] [Related]
43. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
[TBL] [Abstract][Full Text] [Related]
44. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
45. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
46. A new targeting approach for breast cancer gene therapy using the human fatty acid synthase promoter.
Yan C; Wen-Chao L; Hong-Yan Q; Rui Z; Wei-Lin J; Hua H
Acta Oncol; 2007; 46(6):773-81. PubMed ID: 17653900
[TBL] [Abstract][Full Text] [Related]
47. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
48. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.
Kaplan E; Gündüz U
Biomed Pharmacother; 2012 Feb; 66(1):29-35. PubMed ID: 22285073
[TBL] [Abstract][Full Text] [Related]
49. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
Weng MS; Ho CT; Ho YS; Lin JK
Toxicol Appl Pharmacol; 2007 Jan; 218(2):107-18. PubMed ID: 17182072
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.
Menendez JA; Colomer R; Lupu R
Med Hypotheses; 2005; 64(2):337-41. PubMed ID: 15607568
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
[TBL] [Abstract][Full Text] [Related]
52. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
[TBL] [Abstract][Full Text] [Related]
53. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
54. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
55. Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway.
Liu W; Furuta E; Shindo K; Watabe M; Xing F; Pandey PR; Okuda H; Pai SK; Murphy LL; Cao D; Mo YY; Kobayashi A; Iiizumi M; Fukuda K; Xia B; Watabe K
Breast Cancer Res Treat; 2011 Jul; 128(1):57-68. PubMed ID: 20665104
[TBL] [Abstract][Full Text] [Related]
56. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
57. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.
Alli PM; Pinn ML; Jaffee EM; McFadden JM; Kuhajda FP
Oncogene; 2005 Jan; 24(1):39-46. PubMed ID: 15489885
[TBL] [Abstract][Full Text] [Related]
58. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
[TBL] [Abstract][Full Text] [Related]
59. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
60. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]